Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Jeffrey R. Koup"'
Autor:
Daniele Ouellet, Douglas Feltner, John L. Werth, David Hermann, Jeffrey R. Koup, Richard L. Lalonde, Sean D. Donevan, Raymond Miller, Cheryl Li, Wayne Ewy, Peter Lockwood, Ayman El-Kattan, Kenneth G. Kowalski, Brian Corrigan
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 32:185-197
The idea of model-based drug development championed by Lewis Sheiner, in which pharmacostatistical models of drug efficacy and safety are developed from preclinical and available clinical data, offers a quantitative approach to improving drug develop
Autor:
Dennis A. Smith, Susan Hurst, J. Andrew Williams, Theunis C. Goosen, Simon E. Ball, Barry Jones, Vincent Peterkin, Jeffrey R. Koup, Ruth Hyland
Publikováno v:
Drug Metabolism and Disposition. 32:1201-1208
Glucuronidation is a listed clearance mechanism for 1 in 10 of the top 200 prescribed drugs. The objective of this article is to encourage those studying ligand interactions with UDP-glucuronosyltransferases (UGTs) to adequately consider the potentia
Publikováno v:
Clinical Pharmacokinetics. 40:307-315
Objective: Clinafloxacin is a new fluoroquinolone antibacterial with inhibitory activity against aerobic, anaerobic and atypical bacterial pathogens. The objectives of this study are to evaluate the pharmacokinetics of clinafloxacin in healthy volunt
Autor:
Paul H. Siedlik, Jack Cook, Jeffrey R. Koup, Rebecca A. Boyd, Howard N. Bockbrader, Richard L. Lalonde, J. Robert Powell, Stephen C. Olson
Publikováno v:
Clinical Pharmacokinetics. 38:449-459
Continued scepticism about the benefits of population pharmacokinetics and/or population pharmacodynamics, here referred to collectively as the population approach, hampers its widespread application in drug development. At the same time the sources
Autor:
Christine W. Alvey, Jeffrey R. Koup, Edward J. Randinitis, Allen J. Sedman, Cho-Ming Loi, Artemios B. Vassos
Publikováno v:
The Journal of Clinical Pharmacology. 39:920-926
This study evaluated the steady-state pharmacokinetics and dose proportionality of troglitazone, metabolite 1 (sulfate conjugate), and metabolite 3 (quinone metabolite) following administration of daily oral doses of 200, 400, and 600mg troglitazonef
Autor:
Jeffrey R. Koup, Robert A. Blum, Cho-Ming Loi, Allen J. Sedman, Joanne I. Brodfuehrer, Artemios B. Vassos, Philip W. Knowlton, Edward J. Randinitis
Publikováno v:
Clinical Drug Investigation. 17:127-136
Objective: The pharmacokinetic profiles of troglitazone and two metabolites were evaluated following a single 400mg oral dose of troglitazone in 20 patients with various degrees of renal function. Methods: Plasma troglitazone and metabolite concentra
Publikováno v:
Clinical Pharmacokinetics. 37:91-104
Troglitazone is a new thiazolidinedione oral antidiabetic agent approved for use to improve glycaemic control in patients with type 2 diabetes. It is rapidly absorbed with an absolute bioavailability of between 40 and 50%. Food increases the absorpti
Practical Utility of Biomarkers in Drug Discovery and Development covers all aspects of biomarker research applied to drug discovery and development and contains state-of-the-art appraisals on the practical utility of genomic, biochemical, and protei
Publikováno v:
Clinical Chemistry. 44:1474-1480
The cross-reactivity of fosphenytoin, a phosphate ester prodrug of phenytoin, was investigated in the Abbott phenytoin TDx®/TDxFLxTM fluorescence polarization immunoassay (TDx) and the Behring Diagnostics phenytoin Emit® 2000 enzyme-multiplied immu
Publikováno v:
Predictive Approaches in Drug Discovery and Development: Biomarkers and In Vitro/In Vivo Correlations
PREFACE xi ACKNOWLEDGMENTS xiii CONTRIBUTORS xv PART I BIOMARKERS IN DRUG DISCOVERY 1 1 The Importance of Biomarkers in Translational Medicine 3 Joseph C. Fleishaker 2 Validation of Biochemical Biomarker Assays used in Drug Discovery and Development:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26f4b441807649db5344af40196e68da
https://doi.org/10.1002/9781118230275
https://doi.org/10.1002/9781118230275